Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
7
58%
Ph phase_3
3
25%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
7(63.6%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(4)
Other(6)

Detailed Status

unknown6
Completed4
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (9.1%)
Phase 27 (63.6%)
Phase 33 (27.3%)

Trials by Status

unknown650%
recruiting217%
completed433%

Recent Activity

2 active trials
Showing 5 of 12
completedphase_2

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

NCT05519865
completedphase_3

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

NCT04231448
completedphase_2

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

NCT04661943
recruitingphase_3

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

NCT06497985
recruitingphase_3

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

NCT06947967
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05519865Phase 2

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Completed
NCT04231448Phase 3

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Completed
NCT04661943Phase 2

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Completed
NCT06497985Phase 3

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Recruiting
NCT06947967Phase 3

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting
NCT04465097Phase 2

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed
NCT05633914Phase 2

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Unknown
NCT05559008Phase 1

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown
NCT05411380Phase 2

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Unknown
NCT05390476Phase 2

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Unknown
NCT05276713

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Unknown
NCT04999540Phase 2

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12